4th Annual MarketsandMarkets

Next Gen Immuno-Oncology Virtual Congress (Time Zone - GREENWHICH MEAN TIME(GMT))

29th - 30th October, 2020

40+

Speakers

10+

Networking Hours

12+

Sessions

200+

Attendees

In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

Tag Line
30+ experts from academia and industry will be presenting their current work in Immuno-Oncology, Latest updates on regulatory guidelines and approvals, Validation markers for tumor-derived T-cell subpopulations, NextGen T-Cell and CAR-T Cell therapy, Personalized Medicine, Biomarkers and Cancer Immunotherapy
Tag Line
Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.
Tag Line
Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, Validation methods and innovative tools in IO Discovery, Oral T-Cell Therapies for the Treatment of Cancer Patients and Discovery of novel bispecific antibody molecules to boost anti-tumor immunity

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 29th - 30th October 2020 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

WHAT TO EXPECT

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Sessions 

  • Updates in development of monoclonal antibodies, ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Biomarkers and Cancer Vaccines
  • CAR-T cell therapy, T Cell Therapy
  • Tumor microenvironment
  • Oncolytic Viruses
  • Microbiome in Cancer Immunotherapy

CONFERENCE AGENDA

Registration

13:00 - 13:50

Welcome note from MarketsandMarkets

13:50 - 13:55

Selective T Cell Redirection (STR): The Art Triggering A Natural Yet Comprehensive Immune Response In Cold Tumors

Asher Nathan

Asher Nathan , CEO , NeoTX Therapeutics, Israel

18:45 - 19:15

Next Gen Antibodies and Cellular Therapy

Opening remarks from the Chairman

13:55 - 14:00

Keynote: PD-1 Antibodies are Transforming Cancer Care both as Mono- and Combination Therapy

14:00 - 14:30

Avidimabs, Fc engineering to enhanced the avidity of mabs

Lindy Durrant

Lindy Durrant, Professor of Cancer Immunotherapy, CEO, ScanCell Ltd

14:30 - 15:00

CAR T cell research solutions by Miltenyi Biotec

Marcello Stein

Marcello Stein , Global Product Manager, T Cell Immunology , Miltenyi Biotec, Germany

15:00 - 15:30

CAR T-cell immunotherapy of solid tumours: parallel learning from the clinic and lab

John Maher

John Maher, Chief Scientific Officer, Leucid Bio

17:15 - 17:45

Monoclonal Antibodies and Cellular Therapy

Accelerating ImmunoOncology research with Human Primary Cells

Manish	Kumar

Manish Kumar, Product Manager Cells and Media, PromoCell

15:30 - 16:00

IgE class antibodies for cancer treatment: activating the tumour microenvironment

Sophia Karagiannis

Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

16:00 - 16:30

Networking and One-on-One Meetings on the event portal

16:30 - 16:45

In vitro T cell dysfunction / exhaustion-like assays for functional characterization and/or screening of immunomodulatory candidate drugs

Eden Kleiman

Eden Kleiman , Senior Scientist Immuno-oncology, CrownBio

16:45 - 17:15

Development of the next generation immuno-modulators towards the clinic: A humanized anti-BTN3A antibody activating Vγ9Vδ2 T cells

Aude De Gassart

Aude De Gassart , Director of Preclinical Research , ImCheck Therapeutics, France

17:45 - 18:15

A versatile Plug-and-Play platform, BiXAb, for development of bispecific antibodies with diverse set of mechanisms of action

Mustapha Faroudi

Mustapha Faroudi , Director of Immuno Oncology, , Biomunex Pharmaceuticals

18:15 - 18:45

Selective T Cell Redirection (STR): The Art Triggering A Natural Yet Comprehensive Immune Response In Cold Tumors

Asher Nathan

Asher Nathan , CEO , NeoTX Therapeutics, Israel

18:45 - 19:15

Closing Remarks from Chairman

19:15 - 19:20

End of Day 1 and One-one-One Networking

19:20 - 19:20

Immune Checkpoint Inhibitors & Combination Strategies

Opening remarks from the Chairman

Ali Roghanian

Ali Roghanian, Associate Professor, Cancer Immunology & Immunotherapy, University of Southampton

13:55 - 14:00

Keynote: ICI and chemotherapy, why and how?

Stefan Glueck

Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene

14:00 - 14:30

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Illip Burmester, Ph.D.

Illip Burmester, Ph.D. , Scientific Sales Support Europe, Proteome Sciences

14:30 - 15:00

Using CRISPR screens in immune cells to better understand the tumour-immune interface

Nicola McCarthy

Nicola McCarthy , Global Scientific Liaison , Horizon Discovery, UK

15:00 - 15:30

Pre-clinical & Translational Immuno-Oncology Developments

Humanized Mouse Models for Immuno-Oncology Research

Bradlee Heckmann

Bradlee Heckmann, CSO, Asha Therapeutics

15:30 - 16:00

Engineering humanized mouse models of haematological and solid malignancies

Ali Roghanian

Ali Roghanian, Associate Professor, Cancer Immunology & Immunotherapy, University of Southampton

16:00 - 16:30

Networking and One-on-One Meetings on the event portal

16:30 - 16:45

Live Biotherapeutic MRx0518 induces broad anti-tumour immunity and demonstrates potential synergy with checkpoint inhibition

Marsilio Adriani

Marsilio Adriani, Principal Scientist, 4D Pharma

16:45 - 17:15

Enabling the expansive interrogation of a tumor and its microenvironment from a single sample for precision oncology biomarker discovery applications

Maik Pruess PhD

Maik Pruess PhD, Senior Field Application Scientist , Personalis Inc

17:15 - 17:45

Accelerate Therapeutic Antibody and Viral Vectors Manufacturing Partnering with GenScript ProBio

Ben Xu

Ben Xu, BD Director, Biologics Development, GenScript, USA

17:45 - 18:15

Strategies to enhance the efficacy of tumor antigen-specific CAR-based immunotherapy with solid tumors

Soldano Ferrone

Soldano Ferrone, Professor, Harvard University, USA

18:15 - 18:45

Integrin αvβ8-expressing tumor cells serve as a platform for TGF-β activation

Sam Shrivastava

Sam Shrivastava, Chief Executive Officer, Founder, Venn Therapeutics

18:45 - 19:15

Closing Remarks from Chairman

19:15 - 19:20

End of Day 1 and One-one-One Networking

19:20 - 19:20

Registration

13:00 - 13:50

Welcome note from MarketsandMarkets

13:50 - 13:55

Therapeutic Antibodies and Cellular Therapy

Opening remarks from the Chairman

Ann White

Ann White, Senior Principal Scientist, UCB Celltech, UK

13:55 - 14:00

Advances in IO

Specificity profiling of T cell receptor (TCR)-based bispecifics

Stephen Harper

Stephen Harper , Group Leader, Protein Science, Immunocore, UK

14:00 - 14:30

Tumor-localized activation of the immune system using antibody-Anticalin® fusion proteins

Markus Zettl

Markus Zettl , Director, Immuno-Oncology, Pieris Pharmaceuticals, Germany

14:30 - 15:00

MHC-I/MAGE complexes as means for tumor-specific T cell retargeting

Renier Heijkants

Renier Heijkants, Senior Scientist, APO-T

15:00 - 15:30

The Rising Challenges for Patents in Immuno-Oncology

Will Arends

Will Arends , Chartered (UK) and European Patent Attorney, Marks & Clerk, UK

15:30 - 16:00

Arming CAR T cells with Natural killer receptors

David Gilham

David Gilham, Vice President, R&D, Celyad, UK

16:00 - 16:30

Networking and One-on-One Meetings on the event portal

16:30 - 16:45

Panel Discussion: Opening & Introduction to PHC Group, IHC Microfluidics Solutions , Archiving solutions

Steven Lynum, Jennifer Freeland, Grace Robinson

Steven Lynum, Jennifer Freeland, Grace Robinson, ,

16:45 - 17:15

Pre-clinical development of Antibody Drug Conjugates for applications in gynaecological cancers (Skype Presentation)

Deyarina Gonzalez

Deyarina Gonzalez, Professor, Molecular Medicine , Swansea University Medical School, UK

17:15 - 17:45

Unraveling the complexity of the tumor microenvironment using multiplex immunofluorescence

Angela Vasaturo

Angela Vasaturo , Director of Scientific Affairs, Ultivue

17:45 - 18:15

The dark side of IFN gamma – negative feedback regulation of tumour infiltrating T cells by IFN gamma restricts tumour immunity

Audrey Gerard

Audrey Gerard, KTRR Senior Research Fellow , University of Oxford, UK

18:15 - 18:45

Closing Remarks from Chairman

18:45 - 18:50

End of Conference and One-one-One Networking

18:50 - 18:50

Immune Checkpoint Inhibitors and Combinations

Opening remarks from the Chairman

Stefan Glueck

Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene

13:55 - 14:00

Personalized Immunotherapy, Vaccines and Oncolytic Viral Therapy

Invasive tumours and their immunosuppressive functions

Victoria Sanz-Moreno

Victoria Sanz-Moreno , Professor, Cancer Cell Biology , Cancer Research UK Barts Centre, UK

14:00 - 14:30

Mapping the Immune Landscape of High Risk Chemotherapy Resistant Breast Cancers

Sheeba Irshad

Sheeba Irshad, CRUK Clinician Scientist & Honorary Medical Oncologist, Guys Hospital, UK

14:30 - 15:00

Site-selective chemical reactions on proteins; towards homogenous bioconjugates as targeted therapeutics

Archie Wall

Archie Wall , PhD Researcher , University College London, UK

15:00 - 15:30

Delivering Innovative Solutions for Immuno-oncology Drug Discovery

Justyna Rzepecka

Justyna Rzepecka , Principal Scientist Immunology, Concept Lifesciences

15:30 - 16:00

The functional role of B cells within tertiary lymphoid structures in the human tumor microenvironment

Bruno Tullia

Bruno Tullia, Assistant Professor, Immunology, University of Pittsburgh

16:00 - 16:30

Networking and One-on-One Meetings on the event portal

16:30 - 16:45

Attune NxT Acoustic Focusing Flow Cytometer: Efficient. Flexible. Transformative

Idhnan Hussain

Idhnan Hussain , Flow Cytometry Technical Specialist , Thermo Fischer Scientific, UK

16:45 - 17:00

From 2D to 3D imaging: How High Content Screening can take Immuno-Oncology research to the next level

James Watson

James Watson , Senior Business Development Manager, Thermo Fischer Scientific, UK

17:00 - 17:15

Increasing the Targeting Specificity of Immunotherapeutics

Colin Self

Colin Self , CEO, Precision ImmunoTherapeutics

17:15 - 17:45

New opportunities for integrating Immune System Imaging in Clinical trials

Rorn Korn

Rorn Korn , Founder, Chief Medical Officer , Imaging Endpoints, USA

17:45 - 18:15

Closing Remarks from Chairman

18:15 - 18:20

End of Conference and One-one-One Networking

18:20 - 18:20

CONFERENCE SPEAKERS

ADVISORS

Stefan Glueck

Stefan Glueck

Ex- Vice President, Global Head Franchise Oncology, Regeneron

Sophia Karagiannis

Sophia Karagiannis

Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

SPEAKERS

Bruno Tullia

Bruno Tullia

Assistant Professor, Immunology, University of Pittsburgh

Illip Burmester, Ph.D.

Illip Burmester, Ph.D.

Scientific Sales Support Europe, Proteome Sciences

David Gilham

David Gilham

Vice President, R&D, Celyad, UK

John Maher

John Maher

Chief Scientific Officer, Leucid Bio

Sheeba Irshad

Sheeba Irshad

CRUK Clinician Scientist & Honorary Medical Oncologist, Guys Hospital, UK

Will Arends

Will Arends

Chartered (UK) and European Patent Attorney, Marks & Clerk, UK

Markus Zettl

Markus Zettl

Director, Immuno-Oncology , Pieris Pharmaceuticals, Germany

Renier Heijkants

Renier Heijkants

Senior Scientist, APO-T

Sam Shrivastava

Sam Shrivastava

Chief Executive Officer, Founder, Venn Therapeutics

Justyna Rzepecka

Justyna Rzepecka

Principal Scientist Immunology, Concept Lifesciences

Colin Self

Colin Self

CEO, Precision ImmunoTherapeutics

Bradlee Heckmann

Bradlee Heckmann

CSO, Asha Therapeutics

Manish	Kumar

Manish Kumar

Product Manager Cells and Media, PromoCell

Marsilio Adriani

Marsilio Adriani

Principal Scientist, 4D Pharma

Soldano Ferrone

Soldano Ferrone

Professor, Harvard University, USA

Stefan Glueck

Stefan Glueck

Ex- Vice President, Global Head Franchise Oncology, Regeneron

Stephen Harper

Stephen Harper

Group Leader, Protein Science, Immunocore, UK

Sophia Karagiannis

Sophia Karagiannis

Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

Angela Vasaturo

Angela Vasaturo

Director of Scientific Affairs, Ultivue

Ann White

Ann White

Senior Principal Scientist, UCB Celltech, UK

Aude De Gassart

Aude De Gassart

Director of Preclinical Research , ImCheck Therapeutics, France

Ali Roghanian

Ali Roghanian

Associate Professor, Cancer Immunology & Immunotherapy, University of Southampton

Lindy Durrant

Lindy Durrant

Professor of Cancer Immunotherapy, CEO, ScanCell Ltd

Deyarina Gonzalez

Deyarina Gonzalez

Professor, Molecular Medicine , Swansea University Medical School, UK

Audrey Gerard

Audrey Gerard

KTRR Senior Research Fellow , University of Oxford, UK

Marcello Stein

Marcello Stein

Global Product Manager, T Cell Immunology , Miltenyi Biotec, Germany

Maik Pruess PhD

Maik Pruess PhD

Senior Field Application Scientist , Personalis Inc

Rorn Korn

Rorn Korn

Founder, Chief Medical Officer , Imaging Endpoints, USA

Victoria Sanz-Moreno

Victoria Sanz-Moreno

Professor, Cancer Cell Biology , Cancer Research UK Barts Centre, UK

Archie Wall

Archie Wall

PhD Researcher , University College London, UK

Ben Xu

Ben Xu

BD Director, Biologics Development, GenScript, USA

Mustapha Faroudi

Mustapha Faroudi

Director of Immuno Oncology, , Biomunex Pharmaceuticals

Idhnan Hussain

Idhnan Hussain

Flow Cytometry Technical Specialist , Thermo Fischer Scientific, UK

Steven Lynum

Steven Lynum

Executive Director, Global Business Development , PHC Corporation, USA

Jennifer Freeland

Jennifer Freeland

Global Market Development Manager, Immunohistochemistry , EPREDIA

Grace Robinson

Grace Robinson

Global Market Development Manager Archiving, EPREDIA

James Watson

James Watson

Senior Business Development Manager, Thermo Fischer Scientific, UK

Nicola McCarthy

Nicola McCarthy

Global Scientific Liaison , Horizon Discovery, UK

Eden Kleiman

Eden Kleiman

Senior Scientist Immuno-oncology, CrownBio

SPONSORS

PARTNERS